Research programme: GPBAR1 protein agonists - Intercept Pharmaceuticals

Drug Profile

Research programme: GPBAR1 protein agonists - Intercept Pharmaceuticals

Alternative Names: GPBAR1 protein agonists - Intercept Pharmaceuticals; INT-777; S-EMCA; TGR5 protein agonists - Intercept Pharmaceuticals

Latest Information Update: 30 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intercept Pharmaceuticals
  • Class Bile acids and salts; Cholanes; Small molecules
  • Mechanism of Action GPBAR1 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Metabolic disorders; Obesity

Most Recent Events

  • 30 Nov 2017 Preclinical development is ongoing for Metabolic disorders, including Diabetes mellitus and Obesity (Intercept Pharmaceuticals Pipeline, November 2017)
  • 05 Dec 2013 GPBAR1 protein agonist INT 777 is available for licensing as of 05 Dec 2013.
  • 09 Aug 2011 Research programme: GPBAR1 protein agonists licensed to Servier worldwide (excluding USA & Japan)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top